Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 280  
 
ORIGINAL ARTICLE
Ahead of Print

18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of suspected paraneoplastic syndromes: A retrospective analysis


1 Faculty of Medicine and Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
2 Department of Radiology and Imaging Sciences, Emory University Hospital, Atlanta, GA, USA
3 Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA

Correspondence Address:
Ruth Lim,
Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/wjnm.WJNM_48_19

Paraneoplastic syndromes are a rare clinical presentation of tumor thought to affect 0.01% of patients with cancer. Paraneoplastic syndromes present a diagnostic challenge as a wide variety of signs and symptoms may appear. This study examines the use of18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) as a diagnostic imaging tool for detecting tumor in suspected paraneoplastic syndrome cases. This single-center retrospective study included patients with suspected paraneoplastic syndrome who underwent whole-body18F-FDG PET/CT scan between December 2005 and December 2016. Associated clinical data were gathered via electronic chart review. Patient records were reviewed for age, sex, clinical signs and symptoms, ancillary diagnostic procedures, date of diagnosis, and follow-up time. Ninety-nine patients met inclusion criteria for this study. Mean follow-up period was 1.8 years. Cancer prevalence was 12.1%. The18F-FDG PET/CT results are as follows: 10 true positives, 5 false positives, 82 true negatives, and 2 false negatives. The diagnostic values are as follows: sensitivity 83.3%, specificity 94.3%, positive predictive value 66.7%, and negative predictive value (NPV) 97.6%. The high NPV in our study supports the effectiveness of18F-FDG PET/CT to rule out tumor in suspected paraneoplastic syndrome. Future research aims to analyze which patients with suspected paraneoplastic syndrome would benefit most from18F-FDG PET/CT.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Bresler R
    -  Schroeder HW
    -  Chow DZ
    -  Lim R
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed60    
    PDF Downloaded6    

Recommend this journal